Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Quotient Clinical Begins Prostate Cancer Project for Druggability Technologies

publication date: Jul 31, 2015
 | 
author/source: Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer.

Quotient ClinicalThe program will assess new formulations using DRGT’s proprietary Super-API technology, and aims to reduce dose and address food effects associated with the drug.

Quotient’s RapidFACT service provides formulation development, real-time GMP manufacturing and clinical testing, all in one location, creating a streamlined approach to optimizing drug formulations for clinical development. It has been proven to accelerate program timelines by at least 50 % and delivers significant cost savings.

Mark Egerton, CEO of Quotient Clinical, said: “We are delighted that DRGT has selected RapidFACT to support its formulation development project, targeting an important drug in the fight against prostate cancer. This program of work is an excellent illustration of how we can work with our emerging biopharma customers to rapidly validate novel drug delivery technologies and new product concepts.”

Gabor Heltovics, CEO of Druggability technologies, added: “We are very pleased to be working with Quotient on this very important Super-API clinical development program that promises to achieve a major dose reduction, combined with a substantial reduction or elimination of the significant food effects of the marketed drug. The successful application of our Super-API technology to abiratone acetate is yet another important milestone in the development of our oncology drug product portfolio, with the potential to improve the quality of life of patients and help unlock the full potential of drugs that prolong and save lives.”


more about quotient clinical


 



 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events